Base Metals Investing Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer Research
Base Metals Investing Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Base Metals Investing Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer
Base Metals Investing Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Base Metals Investing Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Base Metals Investing Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Base Metals Investing Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
Base Metals Investing Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma
Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients
Locksley Appoints Former U.S. Airforce Major General & General Dynamics IT Executive to Advisory Board
Skyharbour's Partner North Shore Uranium Completes Prospecting Program at the Falcon Project; Significant Radioactivity Discovered in Outcrops and Boulders
